| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-04-04 | 2028-12 | 2027-12 |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | RECRUITING | PHASE1, PHASE2 | 2023-12-27 | 2027-10 | 2026-10 |
| NCT05996445 | A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors | TERMINATED | PHASE1 | 2023-07-28 | 2024-05-21 | 2024-05-21 |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | COMPLETED | PHASE1 | 2022-12-14 | 2025-05-20 | 2025-05-20 |
| NCT06005792 | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-10-10 | 2026-05 | 2026-05 |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-07-21 | 2025-12-30 | 2025-10-15 |
| NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | RECRUITING | PHASE1 | 2022-06-13 | 2027-11 | 2026-02 |
| NCT05328102 | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) | TERMINATED | PHASE2 | 2022-04-15 | 2023-02-21 | 2023-02-21 |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | COMPLETED | PHASE2 | 2021-10-22 | 2025-06-10 | 2025-06-10 |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | TERMINATED | PHASE1, PHASE2 | 2021-05-10 | 2022-03-24 | 2022-03-24 |
| NCT04857866 | Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers | COMPLETED | PHASE1 | 2021-04-19 | 2022-11-10 | 2022-11-10 |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | COMPLETED | PHASE1 | 2019-05-29 | 2023-02-16 | 2023-02-16 |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | COMPLETED | PHASE1 | 2019-05-01 | 2024-02-15 | 2024-02-15 |
| NCT03445663 | Study Evaluating AMG 424 in Subjects With Multiple Myeloma | TERMINATED | PHASE1 | 2018-07-31 | 2020-06-19 | 2020-06-19 |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | COMPLETED | PHASE1 | 2018-07-10 | 2022-09-06 | 2022-06-01 |
| NCT03411915 | A Study of XmAb®18087 in Subjects With NET and GIST | COMPLETED | PHASE1 | 2018-01-22 | 2021-10-26 | 2021-10-26 |
| NCT02924402 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | COMPLETED | PHASE1 | 2016-10 | 2024-04 | 2024-04 |
| NCT02881853 | Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 | COMPLETED | PHASE1 | 2016-08-17 | 2017-02-24 | 2017-02-24 |
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | COMPLETED | PHASE1 | 2016-08 | 2021-09 | 2021-09 |
| NCT02867098 | XmAb5871 Bioavailability Study | COMPLETED | PHASE1 | 2016-07 | 2016-10-21 | 2016-10-21 |
| NCT02725476 | Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) | COMPLETED | PHASE2 | 2016-03 | 2017-12 | 2017-12 |
| NCT02725515 | A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus | COMPLETED | PHASE2 | 2016-02-16 | 2018-07-17 | 2018-07-17 |
| NCT02148744 | Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis | COMPLETED | PHASE1 | 2014-05 | 2015-09-21 | 2015-09-21 |
| NCT01161511 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | COMPLETED | PHASE1 | 2010-09 | 2013-01 | 2013-01 |
| NCT00606645 | Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma | COMPLETED | PHASE1 | 2007-12 | 2010-04 | 2010-04 |